Home » Newsletters » BioWorld Science

BioWorld Science

May 30, 2008

View Archived Issues

Eculizumab inhibits neuropathy in novel mouse model of Miller Fisher syndrome

Brain monoamine oxidase A activity linked to antisocial behavior

Advexin improves survival in recurrent, refractory head and neck cancer

MEDI-563 represents a novel anti-eosinophil therapy for asthma

Effective gastric acid suppression with GSK-1007066A in vivo

Preclinical results reported for TD-8954, a novel 5-HT4 receptor agonist

Taro terminates May 2007 merger agreement with Sun Pharmaceutical

FDA issues nonapprovable letter for The Medicines Company's sNDA for Angiomax

Stem Cell Therapeutics initiates enrollment in phase IIb REGENESIS trial of NTxTM-265

Santarus initiates development of new tablet formulation of Zegerid for GERD

Recent Almirall patent reports new compounds for treating respiratory disorders

Boston Scientific acquires CryoCor

InterMune initiates 14-day triple combination study of ITMN-191 in chronic HCV

Lilly submits sNDA to the FDA for Cymbalta in chronic pain

ViroPharma completes enrollment in phase III maribavir study

New treatment options for HCV infection described in recent patent literature

Alfacell presents phase IIIb results for Onconase trial in malignant mesothelioma

Recent Wisconsin Alumni Research Foundation patents disclose novel antipsoriatic agents

Cell-based osteoprotegerin therapy prevents bone metastasis in prostate cancer model

EMEA notified by sanofi-aventis of its withdrawal of the MAA for Aquilda

Ark Therapeutics to commence pilot phase III Vitor trial in cancer cachexia

Genmab initiates phase I/II zalutumumab combination study in colorectal cancer

GlaxoSmithKline submits NDA for Rezonic/Zunrisa

Nymox reports significant improvement in BPH symptoms after NX-1207 treatment

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...